Treatment of advanced atherosclerotic mice with ABT-263 reduced indices of plaque stability and increased mortality
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
The use of senolytic agents to remove senescent cells from atherosclerotic lesions is controversial. A common limitation of previous studies is the failure to rigorously define the effects of senolytic agent ABT-263 (Navitoclax) on smooth muscle cells (SMC) despite studies claiming that these cells are the major source of senescent cells. Moreover, there are no studies on the effect of ABT-263 on endothelial cells (EC), which - along with SMC - comprise 90% of α-smooth muscle actin+ (α-SMA+) myofibroblast-like cells in the protective fibrous cap. Here we tested the hypothesis that treatment of advanced atherosclerotic mice with ABT-263 will reduce lesion size and increase plaque stability. SMC (Myh11-CreERT2-eYFP) and EC (Cdh5-CreERT2-eYFP) lineage tracing Apoe-/- mice were fed a western diet (WD) for 18 weeks, followed by ABT-263 at 100 mg/kg/bw for 6 weeks or 50 mg/kg/bw for 9 weeks. ABT-263 treatment did not change lesion size or lumen area of the brachiocephalic artery (BCA). However, ABT-263 treatment reduced SMC by 90% and increased EC contributions to lesions via EC-to-mesenchymal transition (EndoMT) by 60%. ABT-263 treatment also reduced α-SMA+ fibrous cap thickness by 60% and was associated with a > 50% mortality rate. Taken together, ABT-263 treatment of WD-fed Apoe-/- mice with advanced lesions resulted in multiple detrimental changes, including reduced indices of stability and increased mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · cited 2×
“…recent murine studies have tested the ability of senolytic agents to remove these senescent cells and to potentially treat a number of major diseases, including atherosclerosis (25, 26, 29, 30), neurodegeneration (38), pulmonary fibrosis (39), diabetic chronic kidney disease (40), and cancer (28).”
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Chang, J., Wang, Y., Shao, L., Laberge, R.-M., Demaria, M., Campisi, J., Janakiraman, K., Sharpless, N. E., Ding, S., Feng, W., et al. (2016) · Nature Medicine · doi:10.1038/nm.4010 · Cited by 1,819 · cited 1×
“ABT-263 inhibits interactions between the antiapoptotic protein BCL-X L and the proapoptotic protein BAX, thus enhancing clearance of senescent cells by reducing their capacity to evade efferocytotic clearance (27).”
BackgroundHickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., Herrmann, S. M., Jensen, M. D., Jia, Q., Jordan, K. L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.069 · Cited by 1,383
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
Justice, J. N., Nambiar, A. M., Tchkonia, T., LeBrasseur, N. K., Pascual, R., Hashmi, S. K., Prata, L., Masternak, M. M., Kritchevsky, S. B., Musi, N., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.052 · Cited by 1,261 · cited 1×
“…recent murine studies have tested the ability of senolytic agents to remove these senescent cells and to potentially treat a number of major diseases, including atherosclerosis (25, 26, 29, 30), neurodegeneration (38), pulmonary fibrosis (39), diabetic chronic kidney disease (40), and cancer (28).”
BackgroundSenolytic drugs: from discovery to translation
Kirkland, J. L., & Tchkonia, T. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13141 · Cited by 1,227
Shankman, L. S., Gomez, D., Cherepanova, O. A., Salmon, M., Alencar, G. F., Haskins, R. M., Swiatlowska, P., Newman, A. A. C., Greene, E. S., Straub, A. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3866 · Cited by 1,218
Self-citationSenescent intimal foam cells are deleterious at all stages of atherosclerosis
Childs, B. G., Baker, D. J., Wijshake, T., Conover, C. A., Campisi, J., & van Deursen, J. M. (2016) · Science · doi:10.1126/science.aaf6659 · Cited by 1,195
Endothelial Cell Senescence in Human Atherosclerosis: Role of Telomere in Endothelial Dysfunction
Minamino, T., Miyauchi, H., Yoshida, T., Ishida, Y., Yoshida, H., & Komuro, I. (2002) · Circulation · doi:10.1161/01.cir.0000013836.85741.17 · Cited by 1,061
Recent insights into the cellular biology of atherosclerosis
Tabas, I., García-Cardeña, G., & Owens, G. K. (2015) · Journal of Cell Biology · doi:10.1083/jcb.201412052 · Cited by 1,016 · cited 1×
“…in atherosclerosis, including macrophages (10), T cells (11), B cells (12), neutrophils (13), endothelial cells (EC) (9), and SMC (4, 14–16), can have beneficial or detrimental effects on lesional development or late-stage pathogenesis depending on the nature of their phenotypic transitions (17).”
BackgroundSelf-citationSenescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks
Sedelnikova, O. A., Horikawa, I., Zimonjic, D. B., Popescu, N. C., Bonner, W. M., & Barrett, J. C. (2004) · Nature Cell Biology · doi:10.1038/ncb1095 · Cited by 790 · cited 1×
“Furthermore, γ - H2AX, another common marker of cellular senescence and a sensitive marker of double-stranded DNA breaks and telomere shortening (33, 34), was also reduced in the fibrous cap of SMC Klf4 –KO BCA as compared with their WT controls (Figure 2, A and B).”
ResultRoos, C. M., Zhang, B., Palmer, A. K., Ogrodnik, M. B., Pirtskhalava, T., Thalji, N. M., Hagler, M., Jurk, D., Smith, L. A., Casaclang‐Verzosa, G., et al. (2016) · Aging Cell · doi:10.1111/acel.12458 · Cited by 738 · cited 2×
“Another independent study from James Kirkland’s lab showed that treatment of Apoe –/– mice with the senolytic agent Dasatinib + Quercetin did not reduce lesion size but reduced plaque calcification (30).”
BackgroundMatthews, C., Gorenne, I., Scott, S., Figg, N., Kirkpatrick, P., Ritchie, A., Goddard, M., & Bennett, M. (2006) · Circulation Research · doi:10.1161/01.res.0000233315.38086.bc · Cited by 615 · cited 1×
“Indeed, previous studies have shown that the atherosclerotic lesions in humans and mice contain relatively large numbers of senescent cells (20–22), and they claim that these senescent cells promote atherosclerosis and contribute to destabilization of plaques (23).”
Tau protein aggregation is associated with cellular senescence in the brain
Musi, N., Valentine, J. M., Sickora, K. R., Baeuerle, E., Thompson, C. S., Shen, Q., & Orr, M. E. (2018) · Aging Cell · doi:10.1111/acel.12840 · Cited by 595 · cited 1×
“…recent murine studies have tested the ability of senolytic agents to remove these senescent cells and to potentially treat a number of major diseases, including atherosclerosis (25, 26, 29, 30), neurodegeneration (38), pulmonary fibrosis (39), diabetic chronic kidney disease (40), and cancer (28).”
BackgroundWhite Cell Telomere Length and Risk of Premature Myocardial Infarction
Brouilette, S., Singh, R. K., Thompson, J. R., Goodall, A. H., & Samani, N. J. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000067426.96344.32 · Cited by 590
Transdifferentiation of Vascular Smooth Muscle Cells to Macrophage-Like Cells During Atherogenesis
Feil, S., Fehrenbacher, B., Lukowski, R., Essmann, F., Schulze-Osthoff, K., Schaller, M., & Feil, R. (2014) · Circulation Research · doi:10.1161/circresaha.115.304634 · Cited by 578 · cited 1×
“However, subsequent studies by our lab (4) and many others (5–8) have either refuted several key aspects of these assumptions or shown that they are overly simplistic.”
Winkels, H., Ehinger, E., Vassallo, M., Buscher, K., Dinh, H. Q., Kobiyama, K., Hamers, A. A. J., Cochain, C., Vafadarnejad, E., Saliba, A.-E., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312513 · Cited by 547 · cited 1×
“Third, there is compelling evidence showing that each of the major cell types involved in atherosclerosis, including macrophages (10), T cells (11), B cells (12), neutrophils (13), endothelial cells (EC) (9), and SMC (4, 14–16), can have beneficial or detrimental effects on lesional development or…”
Vascular Smooth Muscle Cell Senescence Promotes Atherosclerosis and Features of Plaque Vulnerability
Wang, J., Uryga, A. K., Reinhold, J., Figg, N., Baker, L., Finigan, A., Gray, K., Kumar, S., Clarke, M., & Bennett, M. (2015) · Circulation · doi:10.1161/circulationaha.115.016457 · Cited by 349
Cellular senescence and the senescent secretory phenotype in age-related chronic diseases
Zhu, Y., Armstrong, J. L., Tchkonia, T., & Kirkland, J. L. (2014) · Current Opinion in Clinical Nutrition and Metabolic Care · doi:10.1097/mco.0000000000000065 · Cited by 273 · cited 1×
“Senescent cells contribute to age-associated diseases (37), and recent murine studies have tested the ability of senolytic agents to remove these senescent cells and to potentially treat a number of major diseases, including atherosclerosis (25, 26, 29, 30), neurodegeneration (38), pulmonary…”
Activation of the pluripotency factor OCT4 in smooth muscle cells is atheroprotective
Cherepanova, O. A., Gomez, D., Shankman, L. S., Swiatlowska, P., Williams, J., Sarmento, O. F., Alencar, G. F., Hess, D. L., Bevard, M. H., Greene, E. S., et al. (2016) · Nature Medicine · doi:10.1038/nm.4109 · Cited by 221 · cited 1×
“…types involved in atherosclerosis, including macrophages (10), T cells (11), B cells (12), neutrophils (13), endothelial cells (EC) (9), and SMC (4, 14–16), can have beneficial or detrimental effects on lesional development or late-stage pathogenesis depending on the nature of their phenotypic…”
BackgroundSelf-citationKarnewar, S., Neeli, P. K., Panuganti, D., Kotagiri, S., Mallappa, S., Jain, N., Jerald, M. K., & Kotamraju, S. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.01.018 · Cited by 161 · cited 2×
“The method has been described previously (52).”
MethodSelf-citationAgeing induced vascular smooth muscle cell senescence in atherosclerosis
Uryga, A. K., & Bennett, M. R. (2016) · The Journal of Physiology · doi:10.1113/jp270923 · Cited by 160 · cited 1×
“Both p53 and p21 are widely accepted prosenescence markers (32).”
Bär, C., Povedano, J. M., Serrano, R., Benitez-Buelga, C., Popkes, M., Formentini, I., Bobadilla, M., Bosch, F., & Blasco, M. A. (2016) · Blood · doi:10.1182/blood-2015-08-667485 · Cited by 116
Efficacy and limitations of senolysis in atherosclerosis
Garrido, A. M., Kaistha, A., Uryga, A. K., Oc, S., Foote, K., Shah, A., Finigan, A., Figg, N., Dobnikar, L., Jørgensen, H., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab208 · Cited by 83
Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis
Childs, B. G., Zhang, C., Shuja, F., Sturmlechner, I., Trewartha, S., Velasco, R. F., Baker, D. J., Li, H., & van Deursen, J. M. (2021) · Nature Aging · doi:10.1038/s43587-021-00089-5 · Cited by 76 · cited 12×
“…aortic arch lesions of Myh11-CreER T2 TdTomato Ldlr –/– male mice fed a WD for 14 weeks, followed by 9 weeks of a low-fat diet (LFD) and treatment with ABT-263, had a reduced proportion of tdTomato + cells that expressed the osteochondrogenic marker Runx1 as compared with vehicle-treated mice (26).”
BackgroundResultInfluentialWhittemore, K., Derevyanko, A., Martinez, P., Serrano, R., Pumarola, M., Bosch, F., & Blasco, M. A. (2019) · Aging · doi:10.18632/aging.101982 · Cited by 69 · cited 1×
“The P values are indicated on the respective graphs. in the mice reduced vascular senescence and increased lifespan (48), improved myocardial revascularization and tissue repair (49, 50), and reduced neurodegeneration associated with short telomeres (51).”
Background
Cited by
Roadmap for alleviating the manifestations of ageing in the cardiovascular system
Liberale, L., Tual-Chalot, S., Sedej, S., Ministrini, S., Georgiopoulos, G., Grunewald, M., Bäck, M., Bochaton-Piallat, M.-L., Boon, R. A., Ramos, G. C., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01130-5 · Cited by 59
“Nevertheless, in Apoe –/– mice with advanced atherosclerotic lesions and fed a Western-type diet, treatment with navitoclax reduced indices of plaque stability and increased mortality 306 .”
The context-dependent effect of cellular senescence: From embryogenesis and wound healing to aging
Lavarti, R., Alvarez-Diaz, T., Marti, K., Kar, P., & Raju, R. P. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102760 · Cited by 21
Wakita, M., Ito, K., Fujii, K., Sakamoto, D., Mikawa, T., Sugawara, S., Zhou, X., Park, J. H., Miyagawa, H., Motooka, D., et al. (2026) · Nature Aging · doi:10.1038/s43587-025-01057-z · Cited by 9
Proteolysis targeting chimeras as senolytics: An emerging senotherapy for combating aging
Cruickshank-Taylor, A. B., Kozora, J. S., Carew, J. S., Nawrocki, S. T., & Wang, W. (2025) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103752 · Cited by 4
Metadata
- Authors
- Karnewar, S., Karnewar, V., Shankman, L. S., & Owens, G. K.
- Venue
- JCI Insight
- Published
- 2024-01-23
- Volume
- 9
- Issue
- 2
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W4391096142
- Cited by
- 31
- References
- 25
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.